Public Health
Study Overview
This study analyzed the cost-effectiveness of the Japanese multimodal intervention trial for dementia prevention (J-MINT) from a societal viewpoint.
Methodology
We used a Markov model to assess the economic impact of the J-MINT trial, which included participants aged 65 to 85 with mild cognitive impairment. Participants were divided into two groups:
- Intervention Group: Received a combined approach, managing vascular risk factors, physical exercise, nutritional counseling, and cognitive training.
- Standard Care Group: Focused on vascular risk factor management and received health information every two months.
The Markov model included five health states: at-risk, mild, moderate, severe dementia, and death. We estimated care costs and quality-adjusted life years (QALYs) over a lifespan from ages 65 to 100.
Results
The costs for standard care were JPY 18,493,579 and for J-MINT were JPY 18,056,997. The QALYs achieved were 12.37 for standard care and 12.46 for J-MINT. This indicates:
- Savings: JPY 436,582 (approximately US$ 2,952.01)
- QALY Gain: 0.09 per person for J-MINT
This data shows that J-MINT is more cost-effective than standard care.
Conclusion
The findings suggest that multimodal intervention trials like J-MINT offer promising cost-effectiveness for dementia prevention.
Enhancing Clinical Trials
Clinical trials are essential for developing effective treatments. It’s vital to integrate their findings into everyday healthcare practices. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into one accessible resource for healthcare professionals.
Streamlined Operations
Efficient healthcare management is crucial today. Our mobile applications streamline scheduling, treatment monitoring, and telemedicine, simplifying patient care management.
AI Benefits
By leveraging AI, clinics can optimize their workflows, improve patient results, and decrease reliance on paper processes. Discover how we can assist you at aidevmd.com.
